Zilebesiran, a Small Interfering RNA agent as a potential novel antihypertensive treatment with cardiorenal protective effects: An overview of recent clinical trials | [Rawal Medical Journal • 2025]

Author(s):

1. Herwindo Ahmad: Departments of Internal Medicine, Division of Cardiovascular Medicine, Faculty of Medicine, Universitas Sumatera Utara

2. Refli Hasan: Departments of Internal Medicine, Division of Cardiovascular Medicine, Faculty of Medicine, Universitas Sumatera Utara

3. Naomi Niari Dalimunthe: Departments of Internal Medicine, Division of Cardiovascular Medicine, Faculty of Medicine, Universitas Sumatera Utara

4. Rahmad Isnanta: Adam Malik General Hospital, Medan, Indonesia

5. T. Realsyah: Departments of Internal Medicine, Division of Cardiovascular Medicine, Faculty of Medicine, Universitas Sumatera Utara

6. Zainal Safri: Adam Malik General Hospital, Medan, Indonesia

Abstract:

Hypertension is the primary risk factor for kidney and cardiovascular disease. Effective control of hypertension is important as reduction of blood pressure may effectively mitigate cardiovascular risks. The prevalence of uncontrolled hypertension persists, despite the widespread availability of antihypertensive medications. Poor adherence to medications is attributed to inadequate blood pressure control with current treatments. Zilebesiran, an investigational RNA interference therapeutic agent, targets hepatic angiotensinogen synthesis to provide sustained blood pressure reduction. It provides long-lasting pharmacological effects, requiring only twice a year or quarterly subcutaneous injection. There-fore, it is feasible to tackle the inadequate patient comp-liance with this drug. This review discusses its potential clinical impact, efficacy, and safety profile based on re-cent studies.

Page(s): 779-783

DOI: DOI not available

Published: Journal: Rawal Medical Journal, Volume: 50, Issue: 3, Year: 2025

Keywords:

siRNA , Cardiorenal protection , hypertension , antihypertensive agents

References:

[1] Fuchs FD,Whelton PK .2020 .. High Blood Pressure and Cardiovascular Disease. Hypertension, 75 : 285-92.

[2] Unger T,Borghi C,Charchar F,Khan NA,Poulter NR,Prabhakaran D .2020 .. International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75 : 1334-57.

[3] Khalil H,Zeltser R. Antihypertensive H,Available H . .StatPearls Publishing; 2024 Jan-. , : .

[4] Rahimi K,Bidel Z,Nazarzadeh M,Copland E,Canoy D,Ramakrishnan R .2021 .Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, 397 : 1625-36.

[5] Ma J,Chen X. .2022 .Advances in pathogenesis and treatment of essential hypertension. Front Cardiovasc Med, 9 : 1003852.

[6] Burnier M,Egan BM .2019 .. Circ Res, 124 : 1124-40.

[7] Desai AS,Webb DJ,Taubel J,Casey S,Cheng Y,Robbie GJ .2023 .Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med, 389 : 228-38.

[8] Addison ML,Ranasinghe P,Webb DJ .2023 .Emerging insights and prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension. Exp Rev Clin Pharmacol, 16 : 1025-33.

[9] Ranasinghe P,Addison ML,Webb DJ .2022 .Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor-Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen-Targeting Small Interfering RNA. J Am Heart Assoc, 11 : e027694.

[10] Addison ML,Ranasinghe P,Webb DJ .2023 .Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics. Hypertension, 80 : 2243-54.

[11] Kahlon T,Carlisle S,Otero Mostacero D,Williams N,Trainor P,DeFilippis AP .2022 .Angiotensinogen: more than its downstream products: evidence from population studies and novel therapeutics. JACC Heart Fail, 10 : 699-713.

[12] Taubel J,Desai AS,Lasko M,Zee T,Stiglitz D,Rhyee S .2023 .Safety and Tolerability of Zilebesiran, An RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, In Obese Patients with Hypertension. Hypertension, 80 : A116.

[13] Bakris GL,Saxena M,Gupta A,Chalhoub F,Lee J,Stiglitz D .2024 .RNA Interference with Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA, 331 : 740-9.

[14] Saxena M,Aswad A,Badariene J,Kazi F,Karns AD,Neutel JM .2024 .Zilebesiran as add-on therapy in patients with hypertension inadequately controlled with a standard antihypertensive medication: efficacy and safety results from the kardia-2 study. J Hypertens, 42 : e115.

[15] Cruz-López EO,Ye D,Wu C,Lu HS,Uijl E,Mirabito Colafella KM .2022 .Angiotensinogen Suppression: A New Tool to Treat Cardiovascular and Renal Disease. Hypertension, 79 : 2115-126.

[16] Singhania N,Bansal S,Mohandas S,Nimmatoori DP,Ejaz AA,Singhania G .2020 .Role of renin-angiotensin-aldosterone system inhibitors in heart failure and chronic kidney disease. Drug Context, 9 : 1-9.

[17] Mullick AE,Yeh ST,Graham MJ,Engelhardt JA,Prakash TP,Crooke RM .2017 .Blood Pressure Lowering and Safety Improvements with Liver Angiotensinogen Inhibition in Models of Hypertension and Kidney Injury. Hypertension, 70 : 566-76.

[18] Ksiazek SH,Hu L,Andò S,Pirklbauer M,Säemann MD,Ruotolo C .2024 .Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic. Int J Mol Sci, 25 : 4035-9.

[19] Morgan ES,Tami Y,Hu K,Brambatti M,Mullick AE,Geary RS .2021 .Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx: Results of Phase 1 and Phase 2 Studies. JACC Basic Transl Sci, 6 : 485-96.

[20] Bovée DM,Cuevas CA,Zietse R,Danser AHJ,Mirabito Colafella KM,Hoorn EJ .2020 .Salt-sensitive hypertension in chronic kidney disease: distal tubular mechanisms. Am J Physiol Renal Physiol, 319 : 729-45.

[21] Bovée DM,Ren L,Uijl E,Clahsen-Van Groningen MC,Van Veghel R,Garrelds IM .2021 .Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease. Hypertension, 77 : 1600-12.

[22] St. Paul A,Corbett CB,Okune R,Autieri MV,Angiotensin II,Hypercholesterolemia II .2020 .Vascular Smooth Muscle Cells: A Perfect Trio for Vascular Pathology. Int J Mol Sci, 21 : 4525-9.

[23] Wu CH,Mohammadmoradi S,Chen JZ,Sawada H,Daugherty A,Lu HS .2018 .Renin-angiotensin system and cardiovascular functions. Arterioscler Thromb Vasc Biol, 38 : 108-16.

[24] Lu H,Wu C,Howatt DA,Balakrishnan A,Moorleghen JJ,Chen X .2016 .Angiotensinogen exerts effects independent of angiotensin II. Arter Thromb Vasc Biol, 36 : 256-65.

Citations

Downloads

Views